Optimer's Deal With Cubist Gives Dificid Experienced Hospital Sales Force Support
This article was originally published in The Pink Sheet Daily
Executive Summary
Optimer expects the co-promotion to accelerate formulary adoption and uptake of the antibiotic at the 1,100 hospitals where 70% of hospital-related Clostridium dificile infections occur.
You may also be interested in...
Deals Of The Week: Baxter/Gambro, Optimer/AstraZeneca, Ironwood/Protagonist
Three rapid-fire clinical setbacks scuttled a planned merger between BioCryst and Presidio that would have created a new competitor in the hepatitis C space. Now, BioCryst is retrenching with a staff cut and narrower R&D focus.
Optimer Teams With AztraZeneca To Bring Dificid To South America
Optimer has signed a string of partnerships to commercialize the antibiotic around the world; the latest is with AstraZeneca, which will market the drug in South America, Central America, Mexico and the Caribbean.
Optimer Teams With AztraZeneca To Bring Dificid To South America
Optimer has signed a string of partnerships to commercialize the antibiotic around the world; the latest is with AstraZeneca, which will market the drug in South America, Central America, Mexico and the Caribbean.